康华生物
(300841)
| 流通市值：92.41亿 | | | 总市值：100.97亿 |
| 流通股本：1.19亿 | | | 总股本：1.30亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 943,132,559.99 | 863,005,284.96 | 931,949,521.9 | 1,001,326,623.71 |
| 应收票据及应收账款 | 1,315,557,236.92 | 1,263,671,075.73 | 1,211,775,915.46 | 1,298,879,167.25 |
| 应收账款 | 1,315,557,236.92 | 1,263,671,075.73 | 1,211,775,915.46 | 1,298,879,167.25 |
| 预付款项 | 8,268,679.07 | 7,358,447.24 | 11,865,524.24 | 9,936,970.07 |
| 其他应收款合计 | 1,381,952.2 | 1,401,453.26 | 1,509,818.17 | 775,469.16 |
| 存货 | 147,383,087.45 | 179,195,353.62 | 188,083,939.24 | 176,882,114.2 |
| 其他流动资产 | 323,011.22 | 153,997.8 | 9,089,810.09 | 200,757.7 |
| 流动资产合计 | 2,416,046,526.85 | 2,314,785,612.61 | 2,354,274,529.1 | 2,488,001,102.09 |
| 非流动资产: | | | | |
| 长期股权投资 | 6,353,329.95 | 6,353,329.95 | 6,353,329.95 | 6,353,329.95 |
| 其他非流动金融资产 | 406,155,607.36 | 411,924,319.2 | 410,132,731.53 | 410,026,700 |
| 固定资产 | 902,490,513.12 | 919,281,132.18 | 938,121,029.44 | 955,905,539.03 |
| 在建工程 | - | - | 2,759,505.27 | 3,040,600 |
| 无形资产 | 15,888,530.35 | 15,831,018.43 | 16,502,701.01 | 17,513,971.83 |
| 长期待摊费用 | 184,704,620.97 | 162,633,783.73 | 151,028,972.98 | 142,520,407.62 |
| 递延所得税资产 | 4,148,040.81 | 3,127,048.67 | 2,365,900.05 | 2,073,188.56 |
| 其他非流动资产 | 1,709,075.8 | 2,964,781.78 | 2,128,931.72 | 2,147,434.89 |
| 非流动资产合计 | 1,521,449,718.36 | 1,522,115,413.94 | 1,529,393,101.95 | 1,539,581,171.88 |
| 资产总计 | 3,937,496,245.21 | 3,836,901,026.55 | 3,883,667,631.05 | 4,027,582,273.97 |
| 流动负债: | | | | |
| 短期借款 | 149,883,253.92 | 151,313,528.41 | 161,323,081.2 | 186,888,656.44 |
| 应付票据及应付账款 | 1,977,018.32 | 4,983,646.33 | 7,854,097.24 | 5,903,281.65 |
| 其中：应付票据 | - | 937,615.11 | 937,615.11 | 937,615.11 |
| 应付账款 | 1,977,018.32 | 4,046,031.22 | 6,916,482.13 | 4,965,666.54 |
| 合同负债 | 439,662.14 | 458,400 | 988,011.65 | 1,000,749.51 |
| 应付职工薪酬 | 22,850,493.08 | 12,437,070.13 | 10,600,668.63 | 33,366,604.22 |
| 应交税费 | 22,682,803.4 | 8,406,574.83 | 3,114,284.9 | 11,366,004 |
| 其他应付款合计 | 215,032,614.08 | 218,202,699.34 | 222,226,527.98 | 327,813,468.03 |
| 应付股利 | - | - | - | 2,800,937.4 |
| 其他流动负债 | 13,189.86 | 13,752 | 29,640.35 | 30,022.49 |
| 流动负债合计 | 412,879,034.8 | 395,815,671.04 | 406,136,311.95 | 566,368,786.34 |
| 非流动负债: | | | | |
| 预计负债 | 9,573,225.11 | 3,015,599.11 | 3,147,028.12 | 7,537,791.35 |
| 递延收益 | 8,371,467.26 | 5,987,378.63 | 6,167,000 | 6,167,000 |
| 非流动负债合计 | 17,944,692.37 | 9,002,977.74 | 9,314,028.12 | 13,704,791.35 |
| 负债合计 | 430,823,727.17 | 404,818,648.78 | 415,450,340.07 | 580,073,577.69 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 129,946,899 | 132,946,899 | 132,946,899 | 132,946,899 |
| 资本公积 | 861,151,773.51 | 1,082,492,146.04 | 1,082,492,146.04 | 1,082,492,146.04 |
| 减:库存股 | - | 224,340,372.53 | 224,340,372.53 | 224,340,372.53 |
| 盈余公积 | 67,325,224.5 | 67,325,224.5 | 67,325,224.5 | 67,325,224.5 |
| 未分配利润 | 2,448,248,621.03 | 2,373,658,480.76 | 2,409,793,393.97 | 2,389,084,799.27 |
| 归属于母公司股东权益合计 | 3,506,672,518.04 | 3,432,082,377.77 | 3,468,217,290.98 | 3,447,508,696.28 |
| 股东权益合计 | 3,506,672,518.04 | 3,432,082,377.77 | 3,468,217,290.98 | 3,447,508,696.28 |
| 负债和股东权益合计 | 3,937,496,245.21 | 3,836,901,026.55 | 3,883,667,631.05 | 4,027,582,273.97 |
| 公告日期 | 2025-10-17 | 2025-08-26 | 2025-04-19 | 2025-04-19 |
| 审计意见(境内) | | | | 标准无保留意见 |